VivoSeq
Metabolic & Endocrine

Type 1 Diabetic

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Type 1 Diabetic is an early-stage landscape with 0 programs across 3 companies. The most active players are Novo Nordisk, Sanofi, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Completed24 · 71%
Unknown status4 · 12%
Terminated2 · 6%
Withdrawn2 · 6%
Recruiting1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

34 trials

Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients
Recruiting·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT03463564·150 enrolled
Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Not yet recruiting·DDasman Diabetes Institute·Phase 4·NCT06922656·60 enrolled
Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs
Completed·TTanta University·N/A·NCT03660293·150 enrolled
Investigation of the Response Relationship of NN5401 in Type 1 Diabetics
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT00993096·33 enrolled
Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT00760448·25 enrolled
Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls
Completed·VVanderbilt University·N/A·NCT00927524·24 enrolled
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT00992537·27 enrolled
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01925989·27 enrolled
Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients
Completed·Sanofi logoSanofi·Phase 3·NCT00271284·88 enrolled
A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02535715·11 enrolled
A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
Completed·OOPKO Health, Inc.·Phase 1·NCT00239148·20 enrolled
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT00964964·18 enrolled
FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump
Completed·TTexas Diabetes & Endocrinology, P.A.·Phase 3·NCT03977727·40 enrolled
Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients
Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02229097·17 enrolled
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT01002768·28 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)